Clene Inc. Debt Securities, Available-for-sale, Unrealized Loss
Clene Inc. (CLNN) reported Debt Securities, Available-for-sale, Unrealized Loss of $37.00 thousand for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2022-08-15
- Clene Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-06-30 was $37.00K.
- Clene Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2022-03-31 was $50.00K.
- Clene Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2021-06-30 was $0.00.
- Clene Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2021-03-31 was $0.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month |
|---|---|---|
| 2022-06-30 | $37.00K 10-Q · filed 2022-08-15 | $87.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $50.00K 10-Q · filed 2022-05-09 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |